Clinics in Dermatology
Volume 27, Issue 3 , Pages 291-305 , May 2009

Buruli ulcer

  • Françoise Portaels, PhD

      Affiliations

    • Mycobacteriology Unit, Institute of Tropical Medicine, Nationalestraat 155, B-2000 Antwerpen, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 3 247 6317.
    • ,
  • Manuel T. Silva, MD, PhD

      Affiliations

    • Instituto de Biologia Molecular e Celular, 4150-180 Porto, Portugal
    • ,
  • Wayne M. Meyers, MD, PhD

      Affiliations

    • Department of Environmental and Infectious Disease Sciences, Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA

References 

  1. Sizaire V, Nackers F, Comte E, Portaels F. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis. 2006;6:288–296
  2. MacCallum P, Tolhurst JC, Buckle G, Sissons HA. A new mycobacterial infection in man. J Pathol Bacteriol. 1948;60:93–122
  3. Janssens PG, Pattyn SR, Meyers WM, Portaels F. Buruli ulcer: an historical overview with updating to 2005. Bull Séances Acad R Sci Outre-Mer. 2005;51:165–199
  4. Clancey JK, Dodge OG, Lunn HF, Oduori ML. Mycobacterial skin ulcers in Uganda. Lancet. 1961;2:951–954
  5. Dodge OG, Lunn HF. Buruli ulcer: a mycobacterial skin ulcer in a Ugandan child. J Trop Med Hyg. 1962;65:139–142
  6. Aujoulat I, Huguet-Ribas MP, Koita Y. Buruli ulcer: an ignored public health problem [in French]. Dev Santé. 1996;125:22–30
  7. World Health Organization . Buruli ulcer. In:  Asiedu K,  Scherpbier R,  Raviglione M editor. Mycobacterium ulcerans infection. Geneva: World Health Organization; 2000;
  8. World Health Organization . Buruli ulcer disease. Mycobacterium ulcerans infection: an overview of reported cases globally. Wkly Epidemiol Rec. 2004;79:193–200
  9. Debacker M, Aguiar J, Steunou C, et al. Mycobacterium ulcerans disease (Buruli ulcer) in a Rural Hospital, Southern Benin, 1997-2001. Emerg Infect Dis. 2004;10:1391–1398
  10. Johnson RC, Makoutodé M, Sopoh GE, et al. Buruli ulcer in Benin. Emerg Infect Dis. 2005;11:500–501
  11. Stragier P, Ablordey A, Bayonne LM, et al. First report on heterogeneity among Mycobacterium ulcerans from different African countries. Emerg Infect Dis. 2006;12:844–847
  12. Oluwasanmi JO, Solanke TF, Olurin EO, Itayemi SO, Alabi GO, Lucas AO. Mycobacterium ulcerans (Buruli) skin ulceration in Nigeria. Am J Trop Med Hyg. 1976;25:122–128
  13. Perraudin ML, Herrault A, Desbois JC. Mycobacterium ulcerans infection: clinical and bacteriological study of the first cases recognized in South East Asia. Br J Dermatol. 1966;78:187–197
  14. Monson MH, Gibson DW, Connor DH, Kappes R, Hienz HA. Mycobacterium ulcerans in Liberia: a clinicopathologic study of 6 patients with Buruli ulcer. Acta Trop. 1984;41:165–172
  15. Veitch MGK, Johnson PDR, Flood PE, Leslie DE, Street AC, Hayman JA. A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol Infect. 1997;119:313–318
  16. Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers WM. Insects in the transmission of Mycobacterium ulcerans infection (Buruli ulcer). Lancet. 1999;353:986
  17. Marsollier L, Robert R, Aubry J, et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol. 2002;68:4623–4628
  18. Debacker M, Aguiar J, Steunou BSC, et al. Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Trop Med Int Health. 2004;9:1297–1304
  19. Debacker M, Portaels F, Aguiar J, et al. Risk factors for Buruli ulcer, Benin. Emerg Infect Dis. 2006;12:1325–1331
  20. Meyers WM, Shelly WM, Connor DH, Meyers EK. Mycobacterium ulcerans infections developing at sites of trauma to skin. Am J Trop Med Hyg. 1974;23:919–923
  21. Debacker M, Zinsou C, Aguiar J, Meyers WM, Portaels F. First case of Mycobacterium ulcerans disease (Buruli Ulcer) that followed a human bite. Clin Infect Dis. 2003;36:e67–e68
  22. Portaels F, Chemlal K, Elsen P, et al. Mycobacterium ulcerans in wild animals. Rev Sci Tech OIE. 2001;20:252–264
  23. Marsollier L, Sévérin T, Aubry J, et al. Aquatic snails, passive hosts of Mycobacterium ulcerans. Appl Environ Microbiol. 2004;70:6296–6298
  24. Eddyani M, Ofori-Adjei D, Teugels G, et al. Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl Environ Microbiol. 2004;70:5679–5681
  25. Portaels F, Meyers WM. Buruli ulcer. In:  Faber WR,  Hay RJ,  Naafs B editor. Imported skin diseases. Maarssen, The Netherlands: Elsevier Gezondheidszorg; 2006;p. 117–129
  26. Portaels F, Meyers WM, Ablordey A, Castro A, Chemlal K, De Rijk P, et al. First cultivation and characterization of Mycobacterium ulcerans from the environment. PloS Negl Trop Dis. 2008;2:e178
  27. Marsollier L, Deniaux E, Brodin P, et al. Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. PloS Med. 2007;4:e64
  28. Silva MT, Portaels F, Pedrosa J. Aquatic insects and Mycobacterium ulcerans: an association relevant to Buruli ulcer control?. PloS Med. 2007;4:e63
  29. Tonjum T, Welty DB, Jantzen E, Small PL. Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA-DNA hybridization, and 16S rRNA gene sequence analysis. J Clin Microbiol. 1998;36:918–925
  30. Stinear TP, Jenkin GA, Johnson PD, Davies JK. Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol. 2000;182:6322–6330
  31. Mor N, Lutsky I, Levy L. Response in the hindfoot pad and popliteal lymph node of C57BL mice to infection with Mycobacterium marinum. Isr J Med Sci. 1981;17:236–244
  32. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science. 1999;283:854–857
  33. George KM, Pascopella L, Welty DM, Small PL. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun. 2000;68:877–883
  34. Adusumilli S, Mve-Obiang A, Sparer T, Meyers WM, Hayman J, Small PL. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol. 2005;7:1295–1304
  35. Oliveira MS, Fraga AG, Torrado E, et al. Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun. 2005;73:6299–6310
  36. Walsh DS, Meyers WM, Portaels F, et al. High rates of apoptosis in human Mycobacterium ulcerans culture-positive Buruli ulcer skin lesions. Am J Trop Med Hyg. 2005;73:410–415
  37. Gooding TM, Johnson PD, Campbell DE, et al. Immune response to infection with Mycobacterium ulcerans. Infect Immun. 2001;69:1704–1707
  38. Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun. 2002;70:5562–5567
  39. Gooding TM, Kemp AS, Robins-Browne RM, Smith M, Johnson PD. Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis. 2003;36:1076–1077
  40. Prevot G, Bourreau E, Pascalis H, et al. Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun. 2004;72:958–965
  41. Westenbrink BD, Stienstra Y, Huitema MG, et al. Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol. 2005;12:125–129
  42. Stienstra Y, Van Der Graaf WT, te Meerman GJ, The TH, de Leij LF, van der Werf TS. Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Trop Med Int Health. 2001;6:554–562
  43. Kiszewski AE, Becerril E, Aguilar LD, et al. The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol. 2006;143:445–451
  44. Hayman J. Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J Clin Pathol. 1993;46:5–9
  45. Hayman J, McQueen A. The pathology of Mycobacterium ulcerans infection. Pathology. 1985;17:594–600
  46. Van der Werf TS, Van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet. 1999;354:1013–1018
  47. Stanford JL, Revill WD, Gunthorpe WJ, Grange JM. The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg. 1975;74:7–16
  48. Dobos KM, Spotts EA, Marston BJ, Horsburgh CR, King CH. Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease. Emerg Infect Dis. 2000;6:158–164
  49. Marston BJ, Diallo MO, Horsburgh CR, et al. Emergence of Buruli ulcer disease in the Daloa region of Cote d'Ivoire. Am J Trop Med Hyg. 1995;52:219–224
  50. Lagarrigue V, Portaels F, Meyers WM, Aguiar J. Buruli ulcer: risk of bone involvement! A propos of 33 cases observed in Benin. Med Trop. 2000;60:262–266
  51. Noeske J, Kuaban C, Rondini S, et al. Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg. 2004;70:520–526
  52. Portaels F, Aguiar J, Debacker M, et al. BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli Ulcer disease. Infect Immun. 2004;72:62–65
  53. Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun. 2001;69:5403–5411
  54. Coutanceau E, Legras P, Marsollier L, Reysset G, Cole ST, Demangel C. Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer. Microbes Infect. 2006;8:2075–2081
  55. Phillips R, Horsfield C, Kuijper S, et al. Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin Vaccine Immunol. 2006;13:253–257
  56. Phillips R, Horsfield C, Mangan J, et al. Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response. Infect Immun. 2006;74:2917–2924
  57. Fenner F. The pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in the mouse and the developing chick embryo. Am Rev Tuberc. 1956;73:650–673
  58. Krieg RE, Hockmeyer WT, Connor DH. Toxin of Mycobacterium ulcerans. Production and effects in guinea pig skin. Arch Dermatol. 1974;110:783–788
  59. Read JK, Heggie CM, Meyers WM, Connor DH. Cytotoxic activity of Mycobacterium ulcerans. Infect Immun. 1974;9:1114–1122
  60. van der Werf TS, Stienstra Y, Johnson R, et al. Mycobacterium ulcerans disease (Buruli ulcer): a review. Bull WHO. 2005;83:785–791
  61. Johnson PDR, Stinear TP, Small PLC, et al. Buruli-ulcer - new insights into a neglected disease. PLoS Medicine 2005;26:e108:0283-6.
  62. Torrado E, Fraga AG, Castro AG, et al. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun. 2007;75:977–987
  63. Coutanceau E, Marsollier L, Brosch R, et al. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol. 2005;7:1187–1196
  64. Mehta PK, King CH, White EH, Murtagh JJ, Quinn FD. Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication. Infect Immun. 1996;64:2673–2679
  65. Ramakrishnan L, Falkow S. Mycobacterium marinum persists in cultured mammalian cells in a temperature-restricted fashion. Infect Immun. 1994;62:3222–3229
  66. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother. 2003;47:833–836
  67. Kaufmann SH, Cole ST, Mizrahi V, Rubin E, Nathan C. Mycobacterium tuberculosis and the host response. J Exp Med. 2005;201:1693–1697
  68. Turner OC, Keefe RG, Sugawara I, Yamada H, Orme IM. SWR mice are highly susceptible to pulmonary infection with Mycobacterium tuberculosis. Infect Immun. 2003;71:5266–5272
  69. Dobos KM, Quinn FD, Ashford DA, Horsburgh CR, King CH. Emergence of a unique group of necrotizing mycobacterial diseases. Emerg Infect Dis. 1999;5:367–378
  70. Gao LY, Guo S, McLaughlin B, Morisaki H, Engel JN, Brown EJ. A mycobacterial virulence gene cluster extending RD1 is required for cytolysis, bacterial spreading and ESAT-6 secretion. Mol Microbiol. 2004;53:1677–1693
  71. Silva MT, Silva MN, Appelberg R. Neutrophil-macrophage cooperation in the host defence against mycobacterial infections. Microb Pathog. 1989;6:369–380
  72. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol. 1997;61:375–380
  73. Gregory SH, Wing EJ. Neutrophil-Kupffer cell interaction: a critical component of host defenses to systemic bacterial infections. J Leukoc Biol. 2002;72:239–248
  74. Richter-Dahlfors A, Buchan AM, Finlay BB. Murine salmonellosis studied by confocal microscopy: Salmonella typhimurium resides intracellularly inside macrophages and exerts a cytotoxic effect on phagocytes in vivo. J Exp Med. 1997;186:569–580
  75. Rondini S, Horsfield C, Mensah-Quainoo E, Junghanss T, Lucas S, Pluschke G. Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol. 2006;208:119–128
  76. Knodler LA, Finlay BB. Salmonella and apoptosis: to live or let die?. Microbes Infect. 2001;3:1321–1326
  77. Alli OA, Gao LY, Pedersen LL, et al. Temporal pore formation-mediated egress from macrophages and alveolar epithelial cells by Legionella pneumophila. Infect Immun. 2000;68:6431–6440
  78. Huygen K. Prospects for vaccine development against Buruli disease. Expert Rev Vaccines. 2003;2:561–569
  79. Connor DH, Meyers WM, Krieg RE. Infection by Mycobacterium ulcerans. In:  Connor DH,  Binford CH editor. Pathology of Tropical and extraordinary diseases. An atlas. Vol 1:Washington, DC: Armed Forces Institute of Pathology; 1976;p. 26–235
  80. Guarner J, Bartlett J, Whitney EA, et al. Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis. 2003;9:651–656
  81. Dodge OG. Mycobacerial skin ulcers in Uganda: histopathological and experimental aspects. J Pathol Bacteriol. 1964;88:167–174
  82. Meyers WM. Mycobacterial infections of the skin (including leprosy, tuberculosis of the skin, Buruli ulcer, and less common mycobacterial infections). In:  Doerr W,  Seifert G editor. Tropical pathology. 2nd ed.. Berlin: Springer-Verlag; 1995;p. 291–377
  83. Portaels F. Epidemiology of mycobacterial diseases. Clin Dermatol. 1995;13:207–222
  84. Prasad R. Pulmonary sarcoidosis and chronic cutaneous atypical mycobacter ulcer. Aust Fam Physician. 1993;22:755–758
  85. Revill WDL, Morrow RH, Pike MC, Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet. 1973;873–877
  86. Portaels F, Zinsou C, Aguiar J, et al. Les atteintes osseuses dans l'ulcère de Buruli: a propos de 73 cas. Bull Séances Acad R Sci Outre-Mer. 2003;49:161–190
  87. Pszolla N, Sarkar MR, Strecker W, et al. Buruli ulcer–a systemic disease. Clin Infect Dis. 2003;37:e78–e82
  88. In:  Portaels F,  Johnson P,  Meyers WM editor. Buruli ulcer: diagnosis of Mycobacterium ulcerans disease. Geneva: World Health Organization; 2001;
  89. Yip M, Porter JL, Fyfe J, et al. Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor. J Bacteriol. 2007;189:2021–2029
  90. Stragier P, Ablordey A, Durnez L, Portaels F. VNTR analysis differentiates Mycobacterium ulcerans and IS2404 positive mycobacteria. Syst & Appl Microbiol. 2007;30:525–530
  91. World Health Organization . Provisional guidance on the role specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). Geneva: World Health Organization; 2004;
  92. In:  Buntine J,  Crofts K editor. Buruli ulcer: management of Mycobacterium ulcerans disease. Geneva: World Health Organization; 2001;
  93. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Portaels F. Buruli ulcer recurrence, Benin. Emerg Infect Dis. 2005;11:584–589
  94. Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity. Lancet. 2006;367:1849–1858
  95. Guédénon A, Zinsou C, Josse R, et al. Traditional treatment of Buruli ulcer in Bénin. Arch Dermatol. 1995;131:741–742
  96. Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother. 2007;51:4029–4035

PII: S0738-081X(08)00201-0

doi: 10.1016/j.clindermatol.2008.09.021

Clinics in Dermatology
Volume 27, Issue 3 , Pages 291-305 , May 2009

Article Tools

* Image Usage & Resolution